UK Expands Olaparib Maintenance Indication in Ovarian Cancer

December 3, 2019 – The UK’s National Institute for Health and Care Excellence has approved olaparib for the maintenance treatment of adult patients with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease responded to platinum-based chemotherapy and harbor BRCA1/2 mutations. Before this expanded indication, olaparib was available as a capsule formulation within NHS England and Wales via … (leggi tutto)